Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Kadcyla 100mg Injection
Kadcyla 100mg Injection is a specialized treatment indicated for both early and metastatic breast cancer, specifically targeting tumors that express human epidermal growth factor receptor 2 (HER-2).
Uses of Kadcyla 100mg Injection
Kadcyla 100mg Injection is prescribed for:
Treatment of HER-2 positive early breast cancer.
Management of HER-2 positive metastatic breast cancer that has not responded to previous cancer therapies.
Benefits of Kadcyla 100mg Injection
Effectively targets HER-2 positive breast cancer cells, inhibiting their growth and spread.
Provides a targeted treatment option for patients resistant to other cancer medications.
Improves progression-free survival and overall treatment outcomes in advanced breast cancer.
Mechanism of Action of Kadcyla 100mg Injection
Kadcyla 100mg Injection combines trastuzumab, a monoclonal antibody that targets HER-2 receptors, with DM1, a cytotoxic agent. Trastuzumab binds specifically to HER-2 receptors on cancer cells, delivering DM1 directly to the cancer cells. DM1 disrupts microtubule networks essential for cell division, leading to cell death and regression of HER-2 positive tumors.